The FDA has approved Wegovy, Novo Nordisk’s version of semaglutide approved for weight loss, to be used to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
1st weight loss drug approved for treatment of heart conditions
